[go: up one dir, main page]

WO2017011773A3 - Codon-optimized nucleic acids encoding antibodies - Google Patents

Codon-optimized nucleic acids encoding antibodies Download PDF

Info

Publication number
WO2017011773A3
WO2017011773A3 PCT/US2016/042568 US2016042568W WO2017011773A3 WO 2017011773 A3 WO2017011773 A3 WO 2017011773A3 US 2016042568 W US2016042568 W US 2016042568W WO 2017011773 A3 WO2017011773 A3 WO 2017011773A3
Authority
WO
WIPO (PCT)
Prior art keywords
codon
methods
nucleic acids
optimized nucleic
acids encoding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2016/042568
Other languages
French (fr)
Other versions
WO2017011773A2 (en
Inventor
Joseph Beene BOLEN
Stephen Hoge
Iain Mcfadyen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ModernaTx Inc
Original Assignee
ModernaTx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ModernaTx Inc filed Critical ModernaTx Inc
Publication of WO2017011773A2 publication Critical patent/WO2017011773A2/en
Publication of WO2017011773A3 publication Critical patent/WO2017011773A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present disclosure discloses compositions comprising codon-optimized nucleotide sequences, in particular mRNAs, that encode antibodies and functional fragments thereof (e.g., antigen-binding fragments or Fc fragments that can be used in fusion proteins). These optimized nucleic acid sequences can be used to expressing therapeutic antibodies in vivo. Also provided are methods of manufacturing the disclosed codon-optimized nucleotide sequences, methods of generating therapeutic antibodies in a subject in need thereof by administering a polynucleotide comprising a codon-optimized nucleotide sequence, and methods for treating and/preventing a disease or condition in a subject using the disclosed compositions and methods.
PCT/US2016/042568 2015-07-15 2016-07-15 Codon-optimized nucleic acids encoding antibodies Ceased WO2017011773A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562193018P 2015-07-15 2015-07-15
US62/193,018 2015-07-15

Publications (2)

Publication Number Publication Date
WO2017011773A2 WO2017011773A2 (en) 2017-01-19
WO2017011773A3 true WO2017011773A3 (en) 2017-03-23

Family

ID=57757614

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/042568 Ceased WO2017011773A2 (en) 2015-07-15 2016-07-15 Codon-optimized nucleic acids encoding antibodies

Country Status (1)

Country Link
WO (1) WO2017011773A2 (en)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015164674A1 (en) 2014-04-23 2015-10-29 Moderna Therapeutics, Inc. Nucleic acid vaccines
US20170362627A1 (en) * 2014-11-10 2017-12-21 Modernatx, Inc. Multiparametric nucleic acid optimization
HK1256498A1 (en) 2015-07-30 2019-09-27 Modernatx, Inc. Concatemeric peptide epitope rnas
US11564893B2 (en) 2015-08-17 2023-01-31 Modernatx, Inc. Methods for preparing particles and related compositions
DE20164728T1 (en) 2015-10-22 2021-09-30 Modernatx, Inc. RESPIRATORY VACCINE
MA45052A (en) 2016-05-18 2019-03-27 Modernatx Inc POLYNUCLEOTIDES CODING FOR JAGGED1 FOR THE TREATMENT OF ALAGILLUS SYNDROME
JP6983455B2 (en) 2016-09-14 2021-12-17 モデルナティーエックス， インコーポレイテッド High-purity RNA composition and methods for its preparation
WO2018089851A2 (en) 2016-11-11 2018-05-17 Modernatx, Inc. Influenza vaccine
AR110755A1 (en) * 2017-01-20 2019-05-02 Genzyme Corp BONE DIRECTED ANTIBODIES
TWI787230B (en) 2017-01-20 2022-12-21 法商賽諾菲公司 Anti-tgf-beta antibodies and their use
WO2018170245A1 (en) 2017-03-15 2018-09-20 Modernatx, Inc. Broad spectrum influenza virus vaccine
US11752206B2 (en) 2017-03-15 2023-09-12 Modernatx, Inc. Herpes simplex virus vaccine
US20200030432A1 (en) 2017-03-17 2020-01-30 Modernatx, Inc. Zoonotic disease rna vaccines
EP3607074A4 (en) 2017-04-05 2021-07-07 Modernatx, Inc. REDUCTION OR ELIMINATION OF IMMUNE RESPONSES TO NON-INTRAVENOUS, E.G. SUBcutaneously ADMINISTERED THERAPEUTIC PROTEINS
UY37758A (en) * 2017-06-12 2019-01-31 Novartis Ag METHOD OF MANUFACTURING OF BIESPECTIFIC ANTIBODIES, BISPECTIFIC ANTIBODIES AND THERAPEUTIC USE OF SUCH ANTIBODIES
EP3638215A4 (en) 2017-06-15 2021-03-24 Modernatx, Inc. Rna formulations
EP3668977A4 (en) 2017-08-18 2021-04-21 Modernatx, Inc. Analytical hplc methods
ES2983060T3 (en) 2017-08-18 2024-10-21 Modernatx Inc RNA polymerase variants
WO2019036685A1 (en) 2017-08-18 2019-02-21 Modernatx, Inc. Methods for hplc analysis
CN111315359A (en) 2017-08-31 2020-06-19 摩登纳特斯有限公司 Methods of preparing lipid nanoparticles
EP4509527A3 (en) * 2017-10-18 2025-04-30 REGENXBIO Inc. FULLY HUMAN POSTSTRANSLATIONALLY MODIFIED ANTIBODY THERAPEUTIC AGENTS
US11911453B2 (en) 2018-01-29 2024-02-27 Modernatx, Inc. RSV RNA vaccines
WO2020061295A1 (en) 2018-09-19 2020-03-26 Modernatx, Inc. High-purity peg lipids and uses thereof
MA53650A (en) 2018-09-19 2021-07-28 Modernatx Inc PEG LIPIDS AND THEIR USES
CN113271926A (en) 2018-09-20 2021-08-17 摩登纳特斯有限公司 Preparation of lipid nanoparticles and methods of administration thereof
CA3130888A1 (en) 2019-02-20 2020-08-27 Modernatx, Inc. Rna polymerase variants for co-transcriptional capping
JP2022526089A (en) 2019-03-11 2022-05-23 モデルナティエックス インコーポレイテッド Feed batch in vitro transcription process
MA55321A (en) 2019-03-15 2022-01-19 Modernatx Inc RNA VACCINES AGAINST HIV
JP2023545520A (en) 2020-10-14 2023-10-30 ビリジアン セラピューティクス， インコーポレイテッド Compositions and methods for treating thyroid eye disease
EP4247847A1 (en) 2020-11-18 2023-09-27 Novartis AG Bispecific antibodies for use in treatment of nlrc4-gof inflammasomapathy
WO2022150717A1 (en) 2021-01-11 2022-07-14 Modernatx, Inc. Seasonal rna influenza virus vaccines
US20240209068A1 (en) * 2021-04-01 2024-06-27 Modernatx, Inc. Mucosal expression of antibody structures and isotypes by mrna
US20220363937A1 (en) 2021-05-14 2022-11-17 Armstrong World Industries, Inc. Stabilization of antimicrobial coatings
WO2023019171A1 (en) 2021-08-10 2023-02-16 Viridian Therapeutics, Inc. Compositions, doses, and methods for treatment of thyroid eye disease
WO2023030635A1 (en) * 2021-09-02 2023-03-09 BioNTech SE Potency assay for therapeutic potential of coding nucleic acid
WO2023154678A1 (en) * 2022-02-08 2023-08-17 Amgen Inc. Codon-optimized nucleic acids encoding ocrelizumab
PE20251639A1 (en) 2022-06-17 2025-06-24 Apogee Biologics Inc ANTIBODIES THAT BIND TO INTERLEUKIN 13 AND METHODS OF USE
AU2023360978A1 (en) * 2022-10-11 2025-04-17 Ibio, Inc. Epidermal growth factor receptor variant iii antibodies

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090258420A1 (en) * 2005-08-01 2009-10-15 Herman Van Vlijmen Altered polypeptides, immunoconjugates thereof, and methods related thereto
US20140186382A1 (en) * 2002-12-23 2014-07-03 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140186382A1 (en) * 2002-12-23 2014-07-03 Vical Incorporated Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection
US20090258420A1 (en) * 2005-08-01 2009-10-15 Herman Van Vlijmen Altered polypeptides, immunoconjugates thereof, and methods related thereto

Also Published As

Publication number Publication date
WO2017011773A2 (en) 2017-01-19

Similar Documents

Publication Publication Date Title
WO2017011773A3 (en) Codon-optimized nucleic acids encoding antibodies
SA518400424B1 (en) Antibody molecules for cancer treatment
MX359953B (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded therapeutic protein.
AR106752A1 (en) PROTEINS OF UNION TO PD1 / CTLA4
MX2017014083A (en) Anti-cancer fusion polypeptide.
MX2021006615A (en) Trispecific binding proteins and methods of use.
EP4349854A3 (en) Pd1-cd28 fusion proteins and their use in medicine
AU2015286820A8 (en) Stabilization of poly(A) sequence encoding DNA sequences
WO2008054561A3 (en) Proteins, nucleic acids encoding the same and associated methods of use
CR20230026A (en) GDF15 FUSION PROTEINS AND USES OF THESE (DIVISIONAL 2018-0532)
WO2017015619A8 (en) Antibodies to coagulation factor xia and uses thereof
WO2017077329A3 (en) Nucleic acids, peptides and methods
MX2014009909A (en) Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen.
NZ705370A (en) Fcγriib-specific fc region variant
HK1254803A1 (en) Novel pd-1 immune modulating agents
WO2008142164A3 (en) Amino acid sequences directed against rank-l and polypeptides comprising the same for the treatment of bone diseases and disorders
HK1254450A1 (en) Novel fusion polypeptide specific for lag-3 and pd-1
WO2013151670A3 (en) Modified polynucleotides for the production of nuclear proteins
WO2021064137A3 (en) Multi-specific binding proteins for cancer treatment
WO2013040093A3 (en) Glucagon-like peptide-2 compositions and methods of making and using same
WO2007104529A3 (en) Amino acid sequences directed against il-6 and polypeptides comprising the same for the treatment of diseases and disorders associated with il-6-mediated signalling
WO2014202616A3 (en) Rasamsonia gene and use thereof
MX390894B (en) ANTI-CANCER FUSION POLYPEPTIDE.
EA201591131A1 (en) DNA STRUCTURE ANTIBODY AND METHOD OF THEIR APPLICATION
WO2012069655A3 (en) Improved capping modules for designed ankyrin repeat proteins

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16825265

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16825265

Country of ref document: EP

Kind code of ref document: A2